State Stem Cell Agency ICOC Agenda 03-15-07

Day 1
Mar 15, 2007
Main Location: 

Cedars-Sinai Medical Center
Harvey Morse Conference Center
South Professional Tower
8700 Beverly Blvd
Los Angeles, CA 90048

Day 2
Mar 16, 2007
Main Location: 

Cedars-Sinai Medical Center
Harvey Morse Conference Center
South Professional Tower
8700 Beverly Blvd
Los Angeles, CA 90048

 

 

 

California State Stem Cell Agency

 

Regular Meeting of the ICOC to the CIRM

INDEPENDENT CITIZENS’ OVERSIGHT COMMITTEE
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE (CIRM)

Organized Pursuant To The
CALIFORNIA STEM CELL RESEARCH AND CURES ACT

 
Date: March 15-16, 2007 2007

Time: 

  • 3/15/07: 3:00 PM - 10:00 PM (Estimated)
  • 3/16/07: 8:30 AM - 5:00 PM (Estimated)

Location:

  • Cedars-Sinai Medical Center
    Harvey Morse Conference Center
    South Professional Tower
    8700 Beverly Blvd
    Los Angeles, CA 90048
 

OPEN SESSION

  1. Call to Order.
  2. Pledge of Allegiance.
  3. Roll Call.

    [Members of the Public will be invited to provide testimony before or during consideration of each agenda item. Speakers are asked to limit their testimony to three (3) minutes.]

 

CONSENT ITEMS:

  1. Approval of minutes from February 15-16, 2007 ICOC meeting.
 

EXECUTIVE PRESENTATIONS

  1. Chairman’s Report.
  2. President’s Report.
 

ACTION ITEMS

     7.Consideration of appointment of new scientific members and new alternate scientific membes of the Grants
         Review Working Group.
            a. Biographies of proposed new scientific members
            b. Biographies of proposed new alternate members
    8. Consideration of report and potential actions from public session of Grants Review Working Group meeting of
         January 8, 2007, including:
            a. Recommendation that the ICOC amend the Grants Review Working Group bylaws to allow the Chair of
                 the  working group to designate a scientific member to serve as alternate Chairperson in the Chair’s
                 absence during scientific review.
            b. Makes no recommendation regarding designation of an ICOC patient advocate member of the working
                 group by the Vice-Chair to serve as alternate Vice-Chairperson in his or her absence.

             c. Makes no recommendation regarding designation of other patient advocate members of the ICOC to
                 serve as alternates in the absence of any of the ICOC patient advocate members of the Grants Review
                 Working GrouP.

     9. Consideration of amendment to Conflict of Interest Policy for the Grants Review Working Group to
           clarify applicability to specialist members assisting the working group.

     10. Continuation of consideration of Grants Review Working Group’s recommendations regarding Dr. Leon J.
            Thal Memorial SEED Grant applications.


      11. Consideration of Grants Review Working Group’s recommendations regarding Comprehensive Grant
           applications.
                a. Ranked List of Comprehensive Grant Applications
                b. Ranked List of Comprehensive Grant Applications

 

CLOSED SESSION

  1. Discussion of confidential intellectual property or work product and prepublication, confidential scientific research or data relating to Comprehensive and SEED Grant applications (Health & Safety Code 125290.30(d)(3)(B) and (C)).
 

OPEN SESSION

  1. Public report of any action taken, if necessary, during closed session.
  2. Continuation of consideration of Grants Review Working Group’s recommendations regarding Comprehensive Grant applications.
 

CLOSED SESSION
 

15.
       a. Pending Litigation (Government Code section 11126, subdivision (e)): (1) People’s Advocate v. Independent
            Citizens’ Oversight Committee, First District Court of Appeal, Case No. A114282 and California Family  
            Bioethics Council v. California Institute for Regenerative Medicine, First District Court of Appeal, Case No.
            A114195; (2) Mary Scott Doe v. Robert Klein, et al., U.S. Court of Appeals for the Ninth Circuit, Case No.
            06-55387; and (3) National Tax Limitation Foundation v. Westly, Sacramento Court Superior Court, Case No.
            06AS02700.

        b.Discussion of Personnel (Government Code section 11126, subdivision (a); Health & Safety Code section
           125290.30(d)(3)(D)).

 

 

OPEN SESSION

  1. Public report of any action taken, if necessary, during closed session.
 

ACTION ITEMS

  1. Consideration of report from Presidential Search Subcommittee including but not limited to consideration of job description for CIRM President.
  2. Consideration of creation of International Subcommittee including composition of the subcommittee and its mission.
  3. Consideration of report from Governance Subcommittee including but not limited to consideration of Internal Governance Policy.
 

DISCUSSION ITEMS

  1. Public comment. The Committee will accept public testimony on any matter under its jurisdiction that is not on the agenda, but the Committee cannot act on any such matter at this meeting.

     

THE ORDER OF BUSINESS MAY BE CHANGED WITHOUT NOTICE.
Notice is hereby given that the order of consideration of matters on this agenda may be changed without prior notice.



 

**NOTICE**

 

The California Institute for Regenerative Medicine and its Independent Citizens Oversight Committee, and any subcommittees thereof, comply with the Americans with Disabilities Act (ADA) by ensuring that the meeting facilities are accessible to persons with disabilities, and providing that this notice and information given to the Members of the Committee is available to the public in appropriate alternative formats when requested. If you need further assistance, including disability-related modifications or accommodations, you may contact Melissa King at the California Institute for Regenerative Medicine at 415-396-9100 no later than the day prior to the meeting.

Questions or requests for additional information prior to the Independent Citizens Oversight Committee meeting may be referred to Melissa King at the California Institute for Regenerative Medicine at mking@cirm.ca.gov or 415-396-9100.

This meeting agenda is also available on the website for the California Institute for Regenerative Medicine at http://www.cirm.ca.gov.

 

Transcripts: 

© 2013 California Institute for Regenerative Medicine